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Background: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease that
often causes disabling dyspnea. In IPF and other lung diseases, patient-reported outcomes
(PROs)dquestionnaires designed to gather information from the patient’s perspectivedcan
determine whether therapies affect dyspnea or other outcomes meaningful to patients. Before
a PRO can be used confidently as an outcome measure in a longitudinal trial, studies must
demonstrate the PRO’s ability to capture change over time in the target population. Our goal
in this study was to examine whether the UCSD Shortness of Breath Questionnaire does so in
patients with IPF.
Methods: We used data from the Sildenafil Trial of Exercise Performance in Idiopathic Pulmo-
nary Fibrosis (STEP-IPF) to perform analyses that examined associations between UCSD scores
and five external measures (anchors) at baseline and over time. Anchors included the Activity
domain from St. George’s Respiratory Questionnaire (SGRQ-A), the Physical Functioning
domain from the SF-36 (SF36-PF), forced vital capacity (FVC), diffusing capacity of the lung398 1621; fax: þ1 303 398 1040.
.J. Swigris).
2 Elsevier Ltd. All rights reserved.
2.06.018
1448 J.J. Swigris et al.for carbon monoxide (DLCO), and distance walked during a timed walk test (6MWD). Linear
regression models were used to examine relationships between UCSD scores and anchors over
time.
Results: At baseline, UCSD scores were weakly correlated with percent predicted FVC (0.21,
pZ 0.005) and percent predicted DLCO (0.20, pZ 0.008), moderately correlated with 6MWD
(0.39, p < 0.0001) and strongly correlated with SGRQ-A (0.79, p < 0.0001) and SF36-PF
(0.72, p < 0.0001). Change over time in UCSD scores was associated with change in FVC
(estimate Z 2.54, standard error [SE] Z 1.23, p Z 0.04), SGRQ-A (estimate Z 7.94,
SE Z 1.11, p < 0.0001), SF36-PF (estimate Z 6.00, SE Z 1.13, p < 0.0001), and 6MWD
(estimate Z 4.23, SE Z 1.18, p Z 0.0004) but not DLCO (estimate Z 0.33, SE Z 1.33,
p Z 0.80).
Conclusions: These results support the validity of the UCSD to assess change in dyspnea over
time in patients with IPF.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive, fibrosing
interstitial lung disease that causes fatigue, decreased
social participation, and most prominently, disabling dysp-
nea and shortened survival.1 Given the often devastating
effects of IPF and the absence of effective therapies to
prolong life, interest has developed in identifying ways to
improve health-related quality of life (HRQL) in IPF
patients. Key goals include managing dyspnea, cough and
fatigue, increasing physical activity and social participa-
tion, and easing the emotional burden of living with IPF.
Most measures available to assess these outcomes fall in
the category of patient-reported outcome measures
(PROs).
Patient-reported outcome measures attempt to quantify
a person’s perceptions and are administered as question-
naires or surveys, completed by patients themselves, and
target outcomes like health status, HRQL or symptoms
(e.g., dyspnea). Before a PRO can be used confidently as
a trial endpoint in a given population, studies need to be
conducted to show the PRO performs as expected in that
population. For example, prior to using a PRO in a longitu-
dinal IPF trial, existing data should demonstrate its ability
to accurately capture change over time in patients with IPF.
The University of California San Diego Shortness of
Breath questionnaire (UCSD) is a PRO that has been used in
longitudinal research studies, including therapeutic trials in
IPF patients.2,3 Despite its extensive use in IPF, the UCSD’s
basic psychometric properties, including its ability to
capture change in dyspnea over time, have not been
established. We conducted this study to determine the
UCSD’s validity as a PRO capable of assessing dyspnea
longitudinally (i.e., its longitudinal construct validity) in
IPF.Methods
We used data from the Sildenafil Trial of Exercise Perfor-
mance in Idiopathic Pulmonary Fibrosis (STEP-IPF) which
was a placebo-controlled trial designed to examine the
effects of sildenafil in an IPF population with DLCO < 35%predicted.4 Data were collected at baseline, 6, 12, 18 and
24 weeks.
The UCSD
The UCSD is a 24-item dyspnea questionnaire that asks
respondents to rate themselves from 0 (“Not at all”) to 5
(“Maximally or unable to do because of breathlessness”) in
two areas: 1) how short of breath they are while performing
various activities (21 items); and 2) how much shortness of
breath, fear of hurting themselves by overexerting, and
fear of shortness of breath limit them in their daily lives (3
items).5 Scores range from 0 to 120, with higher scores
indicating greater dyspnea.
Anchors
We selected five measures related to dyspnea to serve as
external anchors and hypothesized they would be associ-
ated with UCSD scores. These measures included: (1) forced
vital capacity (FVC), (2) diffusing capacity of the lung for
carbon monoxide (DLCO), (3) distance walked during the 6-
min walk test (6MWD), (4) the Activity domain from St.
George’s Respiratory Questionnaire (SGRQ-A), and (5) the
Physical Functioning domain from the Medical Outcomes
Study Short-form 36-item instrument (SF36-PF). We chose
FVC and DLCO because they are measures used universally
to describe IPF severity.1 Each has been shown in prior
cross-sectional studies to correlate with dyspnea6,7; both
(especially FVC) have been used as primary outcome
measures in IPF trials2,8; and both predict survival in
patients with IPF.9e11 The 6-min walk test (6MWT), and
6MWD in particular, is commonly used as a functional
assessment in patients with IPF. The SGRQ-A assesses
activities that either cause or are limited by dyspnea.
Scores from the SGRQ-A correlate with dyspnea in cross-
sectional studies,12e14 and prior work supports the longi-
tudinal validity of the SGRQ-A in IPF.15 For the SGRQ-A,
higher scores indicate greater impairment. Likewise,
scores from the SF36-PF correlate with dyspnea6,16 and
possess longitudinal validity as a measure of physical
functioning in patients with IPF.15 In contrast to the SGRQ,
lower scores connote greater impairment for the SF-36.
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Characteristic Total subjects Z 180
Age, yrs 69.0 (9.0)
Male, % 83
Time since diagnosis, yrs 2.0 (1.9)
Smoking status, % Current 0
Former 76
Never 24
FVC, liters 2.3 (0.7)
FVC% 56.8 (14.2)
DLCO, ml/min/mmHg 7.8 (2.1)
DLCO% 26.3 (6.1)
6MWD, meters 265.0 (117.1)
UCSD SOB questionnaire 47.0 (21.4)
SGRQ activity domain 69.6 (17.6)
SF36 PF domaina 30.2 (8.4)
Data are percentages or mean (standard deviation);
FVCZ forced vital capacity; FVC%Z percent of predicted FVC
for gender, age, and height; DLCO Z diffusing capacity of the
lung for carbon monoxide; DLCO%Z percent of predicted DLCO
for gender, age and height; 6MWDZ distance walked during 6-
min walk test; UCSD Z University of California San Diego;
SGRQ Z St. George’s Respiratory Questionnaire;
SF36 Z Medical Outcomes Study Short-form 36-item Instru-
ment; PF Z physical functioning.
a Standardized scoring (for theUSgeneral adultpopulation, this
domain has a mean score of 50 with a standard deviation of 10).Weperformed analyses of baseline and longitudinal data.We
used Spearman correlation to examine the relationship
between baseline UCSD scores and values for each of the five
anchors. We used analysis of variance (ANOVA) to compare
mean UCSD change scores (from baseline to 12 weeks as well
as from baseline to 24 weeks) across quartiles of change
within each anchor over the respective time intervals. We
followed the ANOVAs with p-value-adjusted, pair-wise
(parametric and then non-parametric to assess the robust-
ness of) comparisons of mean UCSD change scores between
anchor quartiles while using the quartile of greatest decline
for each anchor as the reference. We also tested for the
presence of linear trends in UCSD change scores over
successive quartiles of change within each anchor.
Next, we used simple linear regression to examine the
association between change (from baseline to 12 weeks and
from baseline to 24 weeks) in UCSD score and change in
anchor values over the same timeframes. After interrogating
the data set and omitting outliers with highly influential
values, we re-ran these analyses. We then used mixed-
effects models to further examine these associations longi-
tudinally, across all study time points. Specifically, for each
anchor, we generated a mixed-effects model with UCSD
score as the outcome variable and the anchor and time as
predictors. In these models, we dichotomized the anchor at
a meaningful cut-point (stable/improved vs. worsened
compared with baseline) and tested the null hypothesis that
UCSD scores would not differ between the dichotomized
subgroups within an anchor over the duration of the study.
For FVC, we considered a decline in the raw value of 7% or
greater as “worsened” and a decline of less than 7% as
“stable/improved.” Our selection of 7% stems fromemerging
data suggesting that small changes in FVC aremeaningful and
prognostically important.17,18 For DLCO, we considered
a decline in the raw value of 15% or greater as “worsened”
and a decline of less than 15% as “stable/improved.”15 For
6MWD, for certain analyses, we considered a decline of 20%
or greater as “worsened” and a lesser decline or improve-
ment as “stable/improved,” and for other analyses, we used
the IPF-specific minimum important difference (MID) esti-
mateof 30mas acut-point.19e21 For the SGRQ-Aand SF36-PF,
we used as cut-points published estimates for their IPF-
specific MIDs (5 and 3 points respectively).15 In the mixed-
effects models, we used an unstructured covariance matrix
(type Z un option in SAS PROC MIXED) to model the corre-
lation structure of the repeated measure.
Next, as a visual representation of the relationship
between UCSD and SGRQ-A or SF36-PF, we generated
cumulative distribution function (CDF) plots for the UCSD
with these anchors using the 24-week data. Finally, we
generated MID estimates for the UCSD using distribution- and
anchor-based approaches. For the distribution-based
approach, we used the effect size, standardized response
mean and standard error of measurement,22 and for the
anchor-based approach, we applied the within-patient
anchor method using the SGRQ-A.23 Institutional review
board approval was not required to perform these analyses
on de-identified, previously collected data. All statistical
analyseswere runusing SAS, Version 9.2 (SAS, Inc.; Cary, NC).Results
Most subjects were male, and the average duration of IPF
was two years (Table 1). At baseline, mean UCSD scores
were weakly correlated with percent predicted FVC (FVC%)
and percent predicted DLCO (DLCO%), moderately corre-
lated with 6MWD, and strongly correlated with SGRQ-A and
SF36-PF scores (Table 2). At 12 and 24 weeks, UCSD change
scores were associated with (and in the hypothesized
direction of) change scores for each of the five anchors
(Table 3). After omitting outliers, as directed by the
DFBETA measure, the results remained the same, except
for the FVC at 12 weeks (beta coefficient 2.4, SE 1.5,
p Z 0.1). From baseline to week 12, UCSD change scores
increased linearly along quartiles of increasing impairment
in SGRQ-A and SF36-PF (p < 0.0001 and p Z 0.0002 for
linear contrasts for the respective anchor). There were
trends toward statistically significant linear increases in
UCSD change scores along quartiles of change in 6MWD and
quartiles of change in FVC over the same time period (Table
4). From baseline to week 24, UCSD change scores
increased linearly along quartiles of increasing impairment
in SGRQ-A and SF36-PF and along quartiles of change in
6MWD. UCSD change scores trended toward statistically
significant linear increases along quartiles of change in FVC
and DLCO over the same time period. The non-parametric
analyses yielded the same results, except the comparison
between the two extreme quartiles for 6MWD at 24 was not
significant (p Z 0.1).
Results from the longitudinal analysis are comparable:
a significant change in UCSD scores was seen in individuals
who experienced clinically significant changes in FVC,
Table 2 Mean UCSD scores per anchor quartile and correlations between baseline UCSD and anchor scores.
Anchor N UCSD Correlation (p-value)
FVC% 0.22 (0.003)
>68 43 43.0 (18.2)
56e68 46 43.8 (22.8)
46e56 45 48.3 (21.3)
<46 45 52.7 (22.1)
DLCO% 0.20 (0.007)
>31 43 42.3 (21.4)
27e31 42 45.3 (22.6)
22e27 49 45.2 (18.7)
<22 46 54.9 (21.4)
6MWD, m 0.39 (<0.0001)
>355 45 36.5 (17.9)
263e355 45 42.9 (21.6)
181e262 45 51.3 (20.8)
<181 45 57.4 (19.6)
SGRQ activity domain 0.80 (<0.0001)
<58 45 26.5 (13.8)
58e71 44 38.5 (10.9)
71e86 44 51.9 (13.3)
>86 46 70.4 (16.3)
SF36 PF domaina 0.72 (<0.0001)
>36 51 28.5 (16.4)
30e36 48 43.1 (11.6)
23e30 46 55.2 (16.7)
<23 34 69.0 (18.5)
Data are percentages or mean (standard deviation); FVCZ forced vital capacity; FVC%Z percent of predicted FVC for gender, age, and
height; DLCO Z diffusing capacity of the lung for carbon monoxide; DLCO% Z percent of predicted DLCO for gender, age and height;
UCSDZ University of California San Diego; SGRQZ St. George’s Respiratory Questionnaire; SF36Z Medical Outcomes Study Short-form
36-item Instrument; PF Z physical functioning.
a Standardized scoring (for the US general adult population, this domain has a mean score of 50 with a standard deviation of 10).
Table 3 Results of linear regression analyses showing association between change in UCSD and change in anchors (as
continuous variables unless otherwise specified) over time.
Baseline to Week 12 Baseline to Week 24
Anchor Estimate (SE) p Anchor Estimate (SE) p
FVC: per 10% change from
baseline in raw FVC
N Z 160
3.96 (1.46) 0.007 FVC: per 10% change
from baseline in raw FVC
N Z 138
4.78 (1.58) 0.003
DLCO: per 10% change from
baseline in raw DLCO
N Z 151
1.19 (0.48) 0.02 DLCO: per 10% change
from baseline in raw FVC
N Z 135
1.15 (0.52) 0.04
6MWD: per 100m change
from baseline 6MWD
N Z 164
2.86 (1.36) 0.04 6MWD: per 100m change
from baseline 6MWD
N Z 140
2.81 (1.41) 0.04
SGRQ-A: per one point change
from baseline in SGRQ-A score
N Z 162
0.62 (0.09) <0.0001 SGRQ-A: per one point
change from baseline
in SGRQ-A score
N Z 139
0.56 (0.08) <0.0001
SF36-PFa: per one point change
from baseline in SF36-PF score
N Z 163
0.75 (0.21) 0.0004 SF36-PFa: per one point
change from baseline in
SF36-PF score
1.03 (0.18) <0.0001
N Z 140
SEZ standard error; FVCZ forced vital capacity; DLCOZ diffusing capacity of the lung for carbon monoxide corrected for hemoglobin;
6MWD Z distance walked during the 6-min walk test; UCSD Z University of California San Diego; SGRQ Z St. George’s Respiratory
Questionnaire; SF36 Z Medical Outcomes Study Short-form 36-item Instrument; PF Z physical functioning.
a Standardized scoring (for the US general adult population, this domain has a mean score of 50 with a standard deviation of 10).
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Table 4 Change from baseline to week 12 (left) or week 24 (right) in UCSD scores according to quartiles of change from
baseline to week 12 or week 24 for each anchor.
Baseline to Week 12
Quartiles of change in anchors N Change in UCSD p
Raw FVC 0.17b
Increase by 2.2% or more 44 1.7 (16.8) 0.18
Increase by 2.1%edrop by 2.7% 45 2.4 (17.4) 0.23
Drop 2.8e7.0% 39 3.7 (14.0) 0.41
Drop by 7.1% or more 41 7.0 (21.2) Reference
Raw DLCO 0.60b
Increase by 11.0% or more 42 4.8 (23.5) 0.42
Increase by 10.9%edrop by 0.6% 45 2.7 (11.5) 0.16
Drop by 0.7e10.9% 43 0.3 (14.1) 0.03
Drop by 11% or more 39 8.1 (19.6) Reference
6MWD 0.08b
Increase by 12 m or more 44 1.5 (17.9) 0.02
Increase by 11edrop by 19 m 41 6.8 (18.5) 0.88
Drop by 20e82 m 42 2.4 (14.4) 0.24
Drop by 83 m or more 42 6.9 (18.4) Reference
SGRQ Activity Score <0.0001þ
Drop by 6.0 points or more 55 5.2 (15.4) <0.0001
Drop 0.0e5.9 points 42 3.1 (13.3) 0.001
Increase 0.1e7.3 points 31 4.9 (17.8) 0.01
Increase by 7.4 points or more 41 14.4 (18.0) Reference
SF36 PF Domaina 0.0002b
Increase by 2.6 points or more 36 3.3 (12.8) <0.0001
Increase by 2.5edrop by 1.2 points 46 1.7 (11.4) 0.003
Drop by 1.1e4.0 points 30 0.9 (15.3) 0.005
Drop by 4.1 points or more 52 11.8 (22.7) Reference
Quartiles of change in anchors N Change in UCSD p
Raw FVC 0.08b
Increase by 1.1% or more 38 5.4 (15.4) 0.20
Increase by 1.0%edrop by 4.9% 38 1.2 (11.6) 0.003
Drop by 5.0e9.7% 35 5.3 (16.6) 0.20
Drop by 9.8% or more 35 10.3 (18.9) Reference
Raw DLCO 0.16b
Increase by 8.0% or more 33 0.9 (13.4) 0.09
Increase by 7.9%edrop by 2.6% 35 6.4 (19.1) 0.78
Drop by 2.6e4.4% 37 4.2 (12.5) 0.40
Drop by 14.5% or more 36 7.4 (18.3) Reference
6MWD 0.02b
Increase by 5.0 m or more 41 0.9 (11.2) 0.03
Increase by 4.9edrop by 36 m 34 4.5 (12.3) 0.49
Drop by 36e114 m 35 8.8 (16.0) 0.65
Drop by 114 m or more 36 7.1 (21.7) Reference
SGRQ Activity Score <0.0001b
Drop by 6.2 points or more 32 6.1 (12.6) <0.0001
Drop by 6.2eincrease by 2.3 points 36 4.3 (12.2) 0.003
Increase by 2.3e12.0 points 36 5.0 (17.2) 0.006
Increase by 12.1 points or more 37 14.5 (15.5) Reference
(continued on next page)
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Quartiles of change in anchors N Change in UCSD p
SF36 PF domaina <0.0001b
Increase by 2.2 points or more 34 4.9 (13.8) <0.0001
Increase by 2.1edrop by 2.0 points 41 2.8 (11.0) 0.0001
Drop by 2.1e6.2 points 31 3.2 (12.5) 0.0005
Drop by 6.3 points or more 40 15.6 (19.0) Reference
Footnote Data are percentages or mean (standard deviation); FVC Z forced vital capacity; DLCO Z diffusing capacity of the lung for
carbon monoxide; UCSDZ University of California San Diego; SGRQZ St. George’s Respiratory Questionnaire; SF36Z Medical Outcomes
Study Short-form 36-item Instrument; PF Z physical functioning.
a Standardized scoring (for the US general adult population, this domain has a mean score of 50 with a standard deviation of 10).
b For overall linear effect.
1452 J.J. Swigris et al.6MWD, SGRQ-A and SF36-PF but not DLCO over the duration
of the study (Table 5). Graphs of the UCSD cumulative
distribution function for the SGRQ-A and SF36-PF anchors
are presented in Fig. 1. Among subjects with UCSD change
scores showing any improvement (0 on the x-axis of the
figures), a greater proportion had improved SGRQ-A (Panel
A) or SF36-PF (Panel B) than stable/worsened SGRQ-A or
SF36-PF. The MID estimates for the UCSD ranged from 5 to
11, with a point estimate of 8 (Table 6).
Discussion
Using data from the STEP-IPF trial, we conducted several
analyses whose results support the construct validity of the
UCSD as an instrument capable of assessing and capturing
change over time in dyspnea in patients with IPF.
Choice of anchors ideally implies that there is a gold
standard for the construct of interest. This is rarely the
case in the assessment of symptoms, and researchers must
rely on either clinical or other patient-reported measures
that are related to the symptom of interest to serve as
anchors. In IPF, there are inextricable links between
pulmonary physiology, functional capacity, HRQL and
dyspnea: 1) as the impairment in pulmonary physiologyTable 5 Results of mixed effects models showing associ-
ation between change in UCSD and worsening in anchors
over time.
Anchor Estimate (SE) p
FVC decline > 7% 2.54 (1.23) 0.04
DLCO decline > 15% 0.33 (1.34) 0.80
6MWD decline > 30 m 3.32 (1.24) 0.008
SGRQ Activity Score
worsening  5 points
7.94 (1.13) <0.0001
SF36 PF Domaina
decline  3 points
6.00 (1.14) <0.0001
SE Z standard error; FVC Z forced vital capacity;
DLCO Z diffusing capacity of the lung for carbon monoxide
corrected for hemoglobin; 6MWDZ distance walked during the
6-min walk test; UCSD Z University of California San Diego;
SGRQ Z St. George’s Respiratory Questionnaire;
SF36 Z Medical Outcomes Study Short-form 36-item Instru-
ment; PF Z physical functioning.
a Standardized scoring (for theUSgeneral adult population, this
domain has a mean score of 50 with a standard deviation of 10).worsens, dyspnea increases; 2) functional capacity
(assessed as either the ability to complete tasks or the rate
at which they are completed) depends greatly on the level
of dyspnea; and 3) dyspnea is a potent driver of HRQL and
health status in patients with IPF.12,24 Hence, in the
absence of a gold standard, we believe FVC, DLCO, 6MWD,
SGRQ-A and SF36-PF were suitable anchors for this study.
From the patient’s perspective, if a therapeutic inter-
vention could improve only one thing in IPF, it would be
dyspnea.24 To assess whether therapies have beneficial (or
adverse) effects on dyspnea, reliable, valid measurement
instruments, sensitive to underlying change in dyspnea, are
needed. Results from our analyses support the use of the
UCSD as such an instrument. In the simple linear regression
analyses, UCSD scores were significantly related to each of
the five anchors. Despite a loss of power, in the ANOVA
analyses, the UCSD was able to discriminate between
subjects who remained stable (or improved) and those who
declined according to the SGRQ-A and SF36-PF at 12 and 24
weeks. From the mixed-effects model, a decline from
baseline in raw FVC of 7% or greater (at 6, 12, 18 or 24
weeks) or in 6MWD of 20% or greater (at 6, 12, 18 or 24
weeks) was associated with a 2.5 or 4.2 point increase
respectively in UCSD score. Likewise, HRQL or health status
worsening at any study time point, defined as change from
baseline by more than the IPF-specific MID for the SGRQ-A
(five points) or the SF36-PF (three points), was associated
with a nearly 8-point or 6-point respective increase in UCSD
score. The CDF graphs provide a different way to look at
UCSD data: a far greater proportion of subjects with stable/
improved UCSD scores had stable/improved, as opposed to
worsened, anchor scores. These types of resultsdwhere
the UCSD can track changes in IPF anchorsdsupport the
longitudinal validity of the UCSD as an instrument capable
of assessing dyspnea over time in IPF patients.
The UCSD is one of several PROs developed to assess
dyspnea. Before investigators can use any PRO confidently,
they need to confirm data exist to support its validity for
a specific purpose, and importantly, in the target pop-
ulation. A PRO has validity if its scores can be used to make
accurate inferences about a patient in the target pop-
ulation. A mistake that has been perpetuated in the
medical literature is that one cross-sectional, correlation
study “validates” an instrument for use in a longitudinal
trial.25 Data from such studies may support the so-called
“concurrent validity” of the instrument but are not suffi-
cient to confirm its ability to assess change in longitudinal
Figure 1 Panel A. Graph of cumulative distribution function for UCSD Change Scores Anchored on Dichotomized SGRQ-A Change
Score at 24 weeks, Footnote: SGRQ-AZ Activity domain from St. George’s Respiratory Questionnaire; Solid lineZ SGRQ-A stable/
improved; dashed lineZ SGRQ-A worsened, Panel B. Graph of cumulative distribution function for UCSD Change Scores Anchored
on Dichotomized SF36-PF Change Score at 24 weeks, Footnote: SF36-PF Z Physical Functioning domain from the SF-36 ques-
tionnaire; Solid line Z SF36-PF stable/improved; dashed line Z SF36-PF worsened.
The UCSD in IPF 1453studies.26e28 One of the key (and anticipated) results from
our study is this: patients with IPF who experience disease
progression report greater dyspnea, as measured by the
UCSD. For example, a decline in raw FVC of 7% or greater
corresponds to a 2.5-point increase in UCSD score. Another
important conclusion is that patients who report a decline
in physical functioning will also develop greater dyspnea, as
measured by the UCSD. Although these findings are intui-
tively obvious, validity is built only after performing anal-
yses, such as these, that confirm the instrument performs
as hypothesized.
It is possible that other dyspnea questionnaireswould yield
similar information under the same circumstances, but until
their longitudinal construct validity is assessed, they cannot
be used confidently in longitudinal IPF research. This is theTable 6 Minimum important difference (MID) estimates for the
0.5 ES 0.5 SRM 1/3 SD 1-SEM SGRQa at 12 we
10.7 12 weeks 7.1 4.8 DUCSD Z 3.1 þ
8.8 For 5e11pt D i
UCSD D 6e10
24 weeks
8.0
ESZ effect size; SDZ standard deviation; SEMZ standard error of m
of breath questionnaire; SGRQ Z St. George’s Respiratory Questionnfirst study to systematically assess the longitudinal construct
validity of any dyspnea questionnaire in IPF. However, data
froma recent study examining the psychometric properties of
FVC in IPF further support our findings.17 In that study, 24-
week change in FVC was significantly correlated with 24-
week change in UCSD score (rZ 0.25, p < 0.001).
Recently, the FDA began formalizing recommendations
for how a PROmight qualify (for the drug indication approval
process) as a valid, reliable outcome measure whose scores
have“interpretablemeaning”andonewhoseutility neednot
be reconfirmed when used again in the same target pop-
ulation.29 To our knowledge, there are no FDA-qualified PROs
for IPF; further, we are unaware if the UCSD is being
considered by the FDA for qualification in IPF. Data reported
here would strongly support such a submission.UCSD.
eks SGRQa at 24 weeks MID
0.6(DSGRQa) DUCSD Z 2.2 þ 0.6(DSGRQa) 8
n SGRQa, 9For 5e11pt D in SGRQa,
UCSD D 5e9
Range
5e11
easurement; UCSDZ University of California San Diego shortness
aire; MID Z minimum important difference.
1454 J.J. Swigris et al.This study has limitations. The first is that subjects in the
STEP-IPF trialdas required for inclusiondhad DLCOs < 35%
predicted. Thus, our results may not apply to IPF patients
with milder disease. However, it seems likely that,
regardless of disease severity at baseline, increasing IPF
severity, or declining HRQL or health status, would lead to
increasing dyspnea (and thus worse UCSD scores). Some of
the analyses yielded results that were not statistically
significant. This is likely due to the variability in measure-
ment of the anchors; for example, DLCO has been recog-
nized by other investigators as statistically noisy, and that
limits the utility of DLCO as a reliable endpoint in IPF
trials.18 Additionally the exclusion of subjects with
DLCO > 35% predicted in STEP-IPF may have introduced
floor effects for this anchor.
Furthermore, dyspnea is a very complex symptom driven
by multiple inputs. Ventilatory restriction and impaired
oxygen diffusion are two (of many) related, but somewhat
independent drivers of dyspnea. This likely explains the
only modest associations between FVC or DLCO and UCSD
scores at baseline. The results of our study cannot be
extended to other dyspnea questionnaires; similar studies
would be required to assess their longitudinal construct
validity in IPF. Despite our results supporting the UCSD in
IPF, it is predominantly focused on how short of breath one
gets with various activities. Thus, investigators should
examine its item content to determine if the UCSD is right
for their particular study. For example, of the UCSD’s 24
items, only two address any aspect of the effect of dyspnea
on mental well-being; if one were interested in determining
the impact of a given treatment on mental health,
a distinct mental health metric would be required. Ours are
the first MID estimates for the UCSD in IPF. The MID should
be calculated in other samples to increase confidence in
our results. For now, we believe 8 is a reasonable point
estimate to use for group-level analyses, and 11 should be
used for individual responder analyses.Conclusion
We used data from a recently completed IPF trial to examine
the ability of the UCSD to assess dyspnea longitudinally. Our
results support the use of the UCSD in IPF trials; however, it is
important to recognize that the UCSD’s primary focus is on
dyspnea associated with physical activity.Funding source
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